Corcept Therapeutics' shares surged nearly 95% as their Phase 3 trial showed positive results in treating resistant ovarian cancer with a new therapy. The promising data could lead to the commercialization of the drug, making it an attractive investment option for the future.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing